11 April 2022 - Gardasil 9 is the first vaccine in Canada approved for the prevention of HPV related oropharyngeal and other head and neck cancers caused by human papillomavirus types 16, 18, 31, 33, 45, 52, and 58.

Merck announced today that Health Canada has approved an expanded indication of Gardasil 9 in individuals 9 through 45 years of age for the prevention of infection caused by the human papillomavirus types 6, 11, 16, 18, 31, 33, 45, 52 and 58 and the following diseases associated with the human papillomavirus types included in the vaccine: oropharyngeal and other head and neck cancers caused by human papillomavirus types 16, 18, 31, 33, 45, 52, and 58.

This market authorisation has been issued with conditions pending the results of trials to verify its clinical benefit.

Read Merck press release